Dual Receptor Recognizing Cell Penetrating Peptide for Selective Targeting, Efficient Intratumoral Diffusion and
Yayuan Liu1, Ling Mei1, Chaoqun Xu2
11. Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, China.
Abstract:
Cell penetrating peptides (CPPs) were widely used for drug delivery to tumor. However, the nonselective in vivo penetration greatly limited the application of CPPs-mediated drug delivery systems. And the treatment of malignant tumors is usually followed by poor prognosis and relapse due to the existence of extravascular core regions of tumor. Thus it is important to endue selective targeting and stronger intratumoral diffusion abilities to CPPs. In this study, an RGD reverse sequence dGR was conjugated to a CPP octa-arginine to form a CendR (R/KXXR/K) motif contained tandem peptide R8-dGR (RRRRRRRRdGR) which could bind to both integrin αvβ3 and neuropilin-1 receptors. The dual receptor recognizing peptide R8-dGR displayed increased cellular uptake and efficient penetration ability into glioma spheroids in vitro. The following in vivo studies indicated the active targeting and intratumoral diffusion capabilities of R8-dGR modified liposomes. When paclitaxel was loaded in the liposomes, PTX-R8-dGR-Lip induced the strongest anti-proliferation effect on both tumor cells and cancer stem cells, and inhibited the formation of vasculogenic mimicry channels in vitro. Finally, the R8-dGR liposomal drug delivery system prolonged the medium survival time of intracranial C6 bearing mice by 2.1-fold compared to the untreated group, and achieved an exhaustive anti-glioma therapy including anti-tumor cells, anti-vasculogenic mimicry and anti-brain cancer stem cells. To sum up, all the results demonstrated that R8-dGR was an ideal dual receptor recognizing CPP with selective glioma targeting and efficient intratumoral diffusion, which could be further used to equip drug delivery system for effective glioma therapy.
Insights
A novel dual-receptor targeting peptide, R8-dGR, enhances drug delivery to gliomas. This peptide-modified liposomal system shows potent anti-tumor effects and improves survival in preclinical models.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Cell penetrating peptides (CPPs) are used for tumor drug delivery but lack in vivo selectivity.
- Malignant tumors often have poor prognosis due to extravascular core regions, necessitating improved targeting and diffusion.
Purpose of the Study:
- To develop a novel peptide for targeted glioma therapy with enhanced cellular uptake and intratumoral diffusion.
- To evaluate the efficacy of R8-dGR modified liposomes loaded with paclitaxel for glioma treatment.
Main Methods:
- Conjugation of octa-arginine (R8) with dGR to create R8-dGR, a dual-receptor targeting peptide (integrin αvβ3 and neuropilin-1).
- In vitro studies using glioma spheroids to assess cellular uptake and penetration.
- In vivo studies using liposomal paclitaxel (PTX-R8-dGR-Lip) in intracranial C6 glioma-bearing mice.
Main Results:
- R8-dGR demonstrated increased cellular uptake and efficient penetration into glioma spheroids.
- PTX-R8-dGR-Lip exhibited strong anti-proliferation effects on tumor cells and cancer stem cells, inhibiting vasculogenic mimicry.
- The R8-dGR liposomal system significantly prolonged survival in mice with intracranial gliomas (2.1-fold increase).
Conclusions:
- R8-dGR is an effective dual-receptor targeting peptide with selective glioma targeting and enhanced intratumoral diffusion capabilities.
- The R8-dGR liposomal drug delivery system offers a promising strategy for comprehensive glioma therapy.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Targeted Cancer Therapies
There are several types of targeted therapies against...
Site-Targeted Drug Delivery Systems: Polymeric Carriers


